Loading stock data…
IMNM
$22.73-0.21 (-0.92%)
Market ClosedLast close May 1
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunome, Inc. in the Healthcare sector is trading at $22.73. The stock is currently 18% below its 52-week high of $27.65, remaining 28.9% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why IMNM maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.73
Potential Upside
5%
Whystock Fair Value$23.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$35.17+54.7%
Range$30.00 – $40.00
Fundamentals
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.83%
Volume
Today's trading volume
949,710
Recent News
A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing
Immunome (IMNM) is back in focus after announcing that Phase 3 data for its desmoid tumor drug candidate, varegacestat, will be featured in an oral session at the 2026 ASCO Annual Meeting. The company also plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second quarter of 2026, a step that moves this program closer to a potential commercial decision point. See our latest analysis for Immunome. The latest ASCO and FDA milestones come after a mixed trading...
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
This biotech innovator in antibody therapeutics reported a notable insider sale amid a year of dramatic share price gains.
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?
Immunome, Inc. recently reported a lower full-year net loss for 2025, updated investors on progress in its oncology pipeline, and filed a US$156.03 million common stock shelf registration tied to an ESOP-related offering. A key angle for investors is how reduced losses alongside an expanded late-stage cancer portfolio and potential future equity issuance could shape Immunome’s financial and operational flexibility. Next, we will examine how Immunome’s reduced net loss and plans to file a New...
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.